Furthermore, the cyclic nonapeptide, CVPELGHEC, had been recognized by ascitic antibodies from patients with stage IV ovarian cancer to a greater degree than stage III in our original study [3], while no difference in gene expression of MMP14 was identified in stage III versus stage IV ovarian cancer in the current study. The gene discussed is MMP14; the disease is ovarian carcinoma.